ASCO Annual Meeting

Zanubrutinib demonstrated a higher complete response or very good partial response rate compared with ibrutinib in patients with Waldenström macroglobulinemia, although the findings were not found to be statistically significant.

Savolitinib showed encouraging efficacy data and an improved safety profile versus sunitinib as a treatment for patients with MET-driven papillary renal cell carcinoma.

Tivozanib demonstrated a significant improvement in progression-free survival when compared with sorafenib, with similar overall survival, in patients with highly relapsed or refractory metastatic renal cell carcinoma.

Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Toni K. Choueiri, MD, discusses results of the phase 3 SAVOIR trial evaluating the MET inhibitor savolitinib versus sunitinib in patients with MET-driven papillary renal cell carcinoma.

Melissa L. Johnson, MD, discusses the results of the phase 2 CITYSCAPE trial in PD-L1–positive non–small cell lung cancer (NSCLC).

Sagar Lonial, MD, FACP, discusses the results of the phase 2 DREAMM-2 trial in multiple myeloma.

Patients with chemotherapy-naïve, locally advanced or metastatic non–small cell lung cancer who were treated in the phase 2 CITYSCAPE trial with tiragolumab, an inhibitor of the immunomodulatory receptor TIGIT, plus and anti–PD-L1 agent demonstrated better efficacy versus single-agent checkpoint inhibitor therapy alone.

The combination of next-generation proteasome inhibitor carfilzomib, lenalidomide, and dexamethasone did not show a superiority in progression-free survival in patients with newly diagnosed multiple myeloma when compared with the current standard of care triplet of bortezomib, lenalidomide and dexamethasone.

Chemotherapy administered within 3 months of a diagnosis of COVID-19 increased the risk of death in patients with thoracic cancer.

The use of real-time comprehensive profiling provides valuable diagnostic information and identifies potential therapeutic targets in adults with malignancies, but this process remains widely underutilized for pediatric patients and represents a significant unmet need.

Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.

Adjuvant treatment with osimertinib demonstrated an 83% reduction in the risk of disease recurrence or death in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer.

Adding avelumab to best supportive care improved the median overall survival by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study.

Pembrolizumab doubled progression-free survival compared with chemotherapy in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer, according to findings from an interim analysis of the phase 3 KEYNOTE-177 trial.

An analysis of data collected in the COVID-19 and Cancer Consortium registry showed that patients with progressive cancer were 5.2-times more likely to die within 30 days of being diagnosed with novel coronavirus 19 compared with patients in remission or with no evidence of disease.

Benoit You, MD, PhD, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab.

Thomas Powles, MD, MBBS, MRCP, discusses the utility of maintenance avelumab in the phase 3 JAVELIN Bladder 100 study in advanced urothelial carcinoma.

We spoke with leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their specialties.

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

The cancer mortality rate declined more in states that expanded Medicaid coverage than those that didn’t following the passage of the Affordable Care Act of 2010, a study found.

The use of video conference technology significantly reduced anxiety and stress among individuals who provide care for an individual with cancer and live more than one hour away from the patient.

Integration of a comprehensive geriatric assessment with geriatrician-led management care improved health-related quality of life, unplanned hospital admissions, and treatment discontinuation among older adults undergoing systemic therapy for their cancer.

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

Treatment with olaparib in the maintenance setting extended overall survival by 12.9 months in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations, compared with placebo, according to randomized phase 3 trial results presented during a 2020 ASCO Virtual Scientific Program press briefing.

The efficacy of larotrectinib is supported in distinct patient populations with TRK fusion cancer—specifically pediatric patients and adult or pediatric patients with brain metastases or primary central nervous system tumors.

Neratinib combined with capecitabine reduced the risk of disease progression or death by 24% compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who received at least 2 prior lines of HER2-targeted therapy.